Syncona’s clinical companies have screened and enrolled the first patient into a clinical trial and are scaling towards late-stage development.
Syncona’s clinical portfolio comprises companies with the potential to treat patients across a range of conditions including: non-small cell lung cancer, melanoma, adrenomyeloneuropathy, Gaucher disease and liver transplantation using a variety of modalities, including small molecules, cell therapy and gene therapy.
Key facts
Unless stated all financials at 30 June 2024.
£283m
Value of clinical portfolio
6
Number of clinical trials
5
Portfolio company Board seats
The clinical stage portfolio pipeline
Best ideas
Pre-clinical
Clinical
Late Clinical
BLA